Medable Secures CNIL Approval, Paving the Way for Digital Clinical Trials in the EU Medable Inc., a global leader in clinical development technology, has reached a significant regulatory milestone with…
NationsBenefits® Reinforces Nutrition-First Approach to GLP-1 Support During National Nutrition Month As National Nutrition Month brings attention to the critical role of healthy eating in disease prevention and overall wellness,…
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The…
Amylyx Reports Q4 and Full-Year 2024 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) recently released its financial results for the fourth quarter and full year ending…
TEVIMBRA Gains U.S. Approval for First-Line Esophageal Cancer Treatment with Chemotherapy BeiGene, Ltd. a global oncology company that has announced its intent to change its name to BeOne Medicines Ltd.,…
Centauri Therapeutics Advances Lead Immunotherapy for Gram-Negative Infections Centauri Therapeutics Limited (Centauri), a pioneering immunotherapy company with a proprietary platform technology applicable across multiple therapeutic areas, has announced the selection…
FairJourney Biologics Acquires Charles River’s South San Francisco Site FairJourney Biologics S.A., a global leader in antibody discovery and optimization, has announced the successful acquisition of the South San Francisco…
Osivax Secures Key Funding to Advance Next-Gen Influenza Vaccines Osivax, a biopharmaceutical company dedicated to developing next-generation vaccines that offer broad-spectrum protection against highly mutating respiratory viruses, has successfully secured…
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong…
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE…
Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual…